I. **AMENDMENTS TO THE SPECIFICATION:**

Please replace the last paragraph on page 29 of the specification with the following amended paragraph.

Table 3 Evaluation of gabapentin and NO-gabapentin analgesic activity in experiment F3 (model of neuropathic pain)

	\\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	1 114	
	Vocalization threshold to pressure in the injured paw (VTPP) (grams)		
Time Post-dosing (min)	Control	gabapentin (175 µmoles/kg, ip)	NO-gabapentin (175 µmoles/kg, ip)
0	144 <u>+</u> 10	160 <u>+</u> 10	153 <u>+</u> 10
5	156 <u>+</u> 10	165 <u>+</u> 23	187 <u>+</u> 10
10	162 <u>+</u> 14	191 <u>+</u> 29	307 <u>+</u> 14
20	150 <u>+</u> 08	250 <u>+</u> 24	325 <u>+</u> 08
40	159 <u>+</u> 11	266 <u>+</u> 26	390 <u>+</u> 11
60	150 <u>+</u> 09	250 <u>+</u> 38	382 <u>+</u> 09